Wantstats
Company ProfilePremium

Canopy Growth Corporation

Company Profile Analysis

Book DemoRegister Your Interest
ESOMAR 23 Corporate BadgeISO Certifications Badge
Canopy Growth Corporation - Healthcare showcase

Year Founded & Workforce

2013

2,000 Employees

Industry

Healthcare

Services

Cannabis Market
C

Canopy Growth Corporation Employee Contacts

4 verified contactsNames, job titles, seniority and locations

View Employee Contacts

Canopy Growth Corporation Overview

Company Headquarters: Ontario, Canada

Founded: 2013

Workforce: ~2,000

Company Working: Canopy Growth Corporation, a well-known Canadian company, is engaged in the production, distribution, and marketing of a wide range of cannabis and hemp-based products across the globe. The company operates through two business segments, namely, cannabis, hemp, & other consumer products and Canopy Rivers Inc. It offers renowned brands in the global market, including BioSteel, TWD, Tweed, Tokyo Smoke, First & Free, and DOJA. The firm has a strong presence in Canada, the US, Germany, the UK, Australia, Denmark, Peru, and Brazil.

Strategy

Canopy has a strong focus on investments in marketing, branding, and product differentiation. The company is aiming to develop a large-scale national platform for the medical cannabis market in Canada. Moreover, the company invests a significant amount of revenue in R&D to develop innovative products. It is offering best-in-class CBD products to gain a consumer base worldwide.

Company Snapshot

$169.5M

Revenue

2,000

Employees

2013

Founded

Ontario, Canada

Headquarters

SWOT Analysis

Strengths

  • Strong capabilities to create strategic alliances and marketing partnerships
  • Well-developed in-house R&D capabilities
  • Strong marketing strategies
  • Skilled workforce
  • Industry leading brands and quality products offerings
  • Good marketing strategies

Weaknesses

  • Competition from local players
  • Price wars with competitors
  • High dependency on Canadian market for revenue generation
  • Decreased R&D investment in 2021

Opportunities

  • Formulation of innovative drugs
  • Collaborative research on pharmaceutical products
  • Mergers & acquisitions to expand in other countries

Threats

  • Government regulations
  • Economic recession
  • Credit risk
  • Fluctuating global economy
  • Changing competitive landscape

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateApproachDevelopment
December 2021AgreementCanopy Growth Corporation entered into an agreement to divest its subsidiary C3 Cannabinoid Compound Co (Germany) and Dermapharm Holding SE (Germany). The C3 develops and manufacture pharmaceutical products. Agreement
April 2021AcquisitionCanopy Growth Corporation acquired Supreme Cannabis Company, Inc. (Canada) to expand the canopy business in Canada.
October 2019AcquisitionCanopy Growth Corporation acquired Beckley Canopy Therapeutics (UK) to increase the clinical research related to the therapeutic use of cannabis.
May 2019AcquisitionCanopy Growth Corporation, which acquired C3 Cannabinoid Compound Co. (Germany), is a leader in cannabinoid-based medical therapies.
February 2019AcquisitionCanopy Growth Corporation and Sequential Brands Group, Inc. (US) announced in collaboration that Martha Stewart (US) joined the company. The Martha Stewart is assisting in developing and positioning a broad new line of product offerings across multiple categories.
November 2018CollaborationCanopy Growth Corporation collaborated with Battelle (US) in order to support canopy’s medical research and novel product development.
August 2018Strategic InvestmentGlobal alcohol giant, Constellation Brands (US), invested USD 5 billion in Canopy Growth Corporation, which is estimated to be the largest strategic investment in cannabis to date. This investment helped the company strengthen its cannabis product portfolio.
April 2018AcquisitionCanopy Growth Corporation acquired Annabis Medical s.r.o. (Czech Republic), expanding Canopy’s focus into another emerging medical cannabis market.

Product Offering

  • Canopy Growth Corporation
    • Cannabis Market

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

By Business Segment: Sales rose from USD 189.8 Mn in 2019 to USD 481.4 Mn in 2021.
Canopy Growth Corporation — By Business Segment
Series (USD Mn)201920202021
Sales189.8311.2481.4
R&D Expenditure11.443.845.7

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.

Get Contacts →